Phaseline

Companies › OncoC4

OncoC4: clinical trials, targets and expected readouts

4 active drug programs in 7 registered trials: 5 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ONC-392 (Gotistobart)
anti-CTLA4 monoclonal antibody
CTLA4Phase 3Non Small Cell Lung Cancer; Ovarian Cancer; Metastatic Castration-resistant Prostate CancerNov 2026
AI-081
Bispecific antibody targeting PD-1 and VEGF
PDCD1, VEGFAPhase 1Advanced Solid TumorJun 2027
ONC-783
Bispecific antibody targeting CD24 and CD3
CD24, CD3Phase 1Advanced Solid TumorAug 2027
ONC-841
Anti-SIGLEC10 antibody with IgG4 Fc domain
SIGLEC10Phase 1Advanced Solid TumorSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05682443ONC-392 (Gotistobart)Phase 1Metastatic Castration-resistant Prostate CancerOncologyNov 2026
NCT04140526ONC-392 (Gotistobart)Phase 1Non Small Cell Lung CancerOncologyDec 2026
NCT06635785AI-081Phase 1Advanced Solid TumorOncologyJun 2027
NCT07408258ONC-783Phase 1Advanced Solid TumorOncologyAug 2027
NCT05446298ONC-392 (Gotistobart)Phase 2Ovarian CancerOncologyAug 2027
NCT05671510ONC-392 (Gotistobart)Phase 3Non Small Cell Lung CancerOncologyAug 2027
NCT06352359ONC-841Phase 1Advanced Solid TumorOncologySep 2027

Targets

CD24 (1) CD3 (1) CTLA4 (1) SIGLEC10 (1) PDCD1 (1) VEGFA (1)

Companies with the same targets

AstraZeneca Akeso Innovent Biologics (Suzhou) Shanghai Henlius Biotech Roche Sichuan Baili Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical MacroGenics Innovent Biopharmaceutical Technology (Hangzhou)

Companies built like this

Agenus AskGene Pharma MacroGenics CrystalGenomics Lepu Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.